Immunovant, Inc.

NASDAQ:IMVT

19.61 (USD) • At close March 11, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q32025 Q22025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 0001.50000000000000000.9260000000
Cost of Revenue 000.080.0640.0580.3490.3430.3410.3330.3270.3230.3140.3130.3050.30.2410000.46300.3950.0680000
Gross Profit 00-0.081.436-0.058-0.349-0.343-0.341-0.333-0.327-0.323-0.314-0.313-0.305-0.3-0.2410000.4630-0.395-0.0680000
Gross Profit Ratio 0000.9570000000000000000.50000000
Reseach & Development Expenses 94.5297.27275.47366.05648.33847.95950.57551.83742.25237.73928.42931.98629.75621.36118.70518.61521.09111.97616.92214.1684.95310.33118.4767.977.6835.7454.335
General & Administrative Expenses 19.78218.47118.80814.82313.21513.84115.40212.42211.77511.87511.94615.24111.51516.28911.18110.30210.5498.9989.6646.3156.0884.1631.5850.9631.2010.4950.033
Selling & Marketing Expenses 00-0.08-0.06400000000000000000000000
SG&A 19.78218.47118.72814.75913.21513.84115.40212.42211.77511.87511.94615.24111.51516.28911.18110.30210.5498.9989.6646.3156.0884.1631.5850.9631.2010.4950.033
Other Expenses 000.028-2.5871.0940.020.4640.356-1.7570.7930.3540.044-0.114-0.084-0.6260.68-0.5030.225-0.074-0.1270.2210.420.0920000
Operating Expenses 114.302115.74394.20180.81561.55361.865.97764.25954.02749.61440.37547.22741.27137.6529.88628.91731.6420.97426.58620.48311.0410.420.09208.8416.3464.368
Operating Income -114.302-115.743-94.281-80.879-51.526-58.208-73.948-64.313-44.027-49.614-40.375-47.266-41.385-37.65-29.886-28.917-31.64-20.974-26.586-20.483-11.041-0.42-0.092-0-8.884-6.24-4.368
Operating Income Ratio 000-53.919000000000000000-22.1250000000
Total Other Income Expenses Net 3.3326.7027.2085.79210.0273.5924.52913.836-8.8131.9470.3540.044-0.114-0.084-0.6260.68-0.5030.225-0.074-0.127-0.1550.6830.34200.043-0.106-0
Income Before Tax -110.97-109.041-87.073-75.087-51.526-58.208-73.948-60.423-62.84-47.667-40.021-47.183-41.385-37.734-30.512-28.237-32.143-20.749-26.66-20.61-11.1960.2630.249-0-8.841-6.346-4.368
Income Before Tax Ratio 000-50.058000000000000000-22.2620000000
Income Tax Expense 0.1520.0780.0770.232-0.1080.454-0.011-0.9920.3870.2610.352-0.012-0.28-0.031-0.041-0.079-0.3670.040.048-0.0590.10.1380.0660.0070.0080.004-0
Net Income -111.122-109.119-87.15-75.319-51.418-58.662-73.937-59.431-63.227-47.928-40.373-47.171-41.385-37.703-30.471-28.158-31.776-20.789-26.708-20.551-11.2960.1250.183-0-8.849-6.35-4.368
Net Income Ratio 000-50.213000000000000000-22.1980000000
EPS -0.76-0.74-0.6-0.52-0.36-0.45-0.57-0.46-0.49-0.41-0.35-0.41-0.36-0.35-0.31-0.29-0.32-0.21-0.32-0.29-0.280.0440.0160-0.24-0.36-0.44
EPS Diluted -0.76-0.74-0.6-0.52-0.36-0.45-0.57-0.46-0.49-0.41-0.35-0.41-0.36-0.35-0.31-0.29-0.32-0.21-0.32-0.29-0.280.0090.064-0-0.24-0.36-0.44
EBITDA -114.203-115.654-94.201-80.815-61.495-61.744-65.924-64.205-53.978-49.568-40.331-47.188-41.238-37.429-29.86-28.28-31.621-20.96-26.576-20.604-10.82-0.42-0.092-0-8.88300
EBITDA Ratio 000-53.877000000000000000-22.2550000000